NCT00629967View on ClinicalTrials.gov

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

May 31, 2007

Study Completion Date

May 31, 2007

Conditions
Chronic Hepatitis CGenotype
Interventions
DRUG

pegylated interferon alpha 2a and ribavirin

pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks

DRUG

Pegylated interferon alfa-2a and ribavirin

Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks

Trial Locations (1)

807

Kaohsiung Medical University Hospital, Kaohsiung City

All Listed Sponsors
lead

Kaohsiung Medical University Chung-Ho Memorial Hospital

OTHER

NCT00629967 - A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-1 Patients | Biotech Hunter | Biotech Hunter